Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640353 | 1.00 | DCUN1D1 (1.00) | DCUN1D1UBE2M | |
| SCHEMBL29491119 | 0.95 | UBE2M (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18657955 | 0.95 | UBE2M (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18640251 | 0.88 | UBE2M (1.00) | DCUN1D1UBE2M | |
| SCHEMBL29491067 | 0.88 | UBE2M (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18657392 | 0.87 | DCUN1D1 (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18640272 | 0.86 | DCUN1D1 (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18657664 | 0.85 | UBE2M (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18640341 | 0.84 | DCUN1D1 (1.00) | DCUN1D1UBE2M | |
| SCHEMBL18640228 | 0.83 | DCUN1D1 (1.00) | DCUN1D1UBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | DCUN1D1 10/4885UBE2M 12/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DCUN1D1 3/4885UBE2M 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.